Delhi High Court Remands Array BioPharma Cancer Combination Patent Application for Fresh Reconsideration
Array BioPharma Inc. Vs. Deputy Controller of Patents and Designs:23.07.2026:C.A.(COMM.IPD-PAT) 37/2023:2026:DHC:5856:Hon'ble Mr. Justice Tushar Rao Gedela
Factual and Procedural Background
Array BioPharma Inc. filed Indian Patent Application No. 450/DELNP/2015 on January 19, 2015, titled "PHARMACEUTICAL COMBINATION COMPRISING A BRAF INHIBITOR AN EGFR INHIBITOR AND OPTIONALLY A PI3K ALPHA INHIBITOR", tracing priority to a US application filed on August 7, 2012. Following the issuance of the First Examination Report and multiple rounds of hearings, the Deputy Controller of Patents and Designs passed an order on June 30, 2023 under Section 15 of the Patents Act, 1970, refusing the grant of patent. The refusal was based on grounds of lack of inventive step under Section 2(1)(ja), non-patentability under Section 3(d), non-patentability under Section 3(i), and non-compliance with Section 10(4) and Section 10(5). Aggrieved by this rejection, the applicant filed an appeal under Section 117A of the Patents Act before the High Court of Delhi.
Dispute before Court
The central dispute was whether the claimed pharmaceutical combination comprising a B-Raf inhibitor (Encorafenib), an EGFR inhibitor (Cetuximab or Erlotinib), and optionally a PI3K-alpha inhibitor (Alpelisib) lacked an inventive step over prior art citations D1 to D4. Additionally, the Court had to determine whether the subject application fell under the statutory bar of Section 3(d) as a non-patentable form or derivative of a known substance without enhanced efficacy, and whether the phrase "for simultaneous, separate or sequential administration" transformed a product combination claim into a non-patentable method of treatment under Section 3(i) of the Patents Act, 1970.
Reasoning of Judge
The Court observed that none of the cited prior art documents D1 to D4 disclosed or suggested the specific dual or triple combination of Encorafenib, Cetuximab/Erlotinib, and Alpelisib, nor did they provide any motivation for a person skilled in the art to combine these precise active pharmaceutical agents. The Controller failed to conduct a proper analysis of inventive step or identify any technical problem solved over the closest prior art. Regarding Section 3(d), the Court held that the provision applies when an invention is a new form of a known substance, and the Controller failed to identify any base "known compound" of which the claimed combination was alleged to be a derivative. On Section 3(i), the Court affirmed that Claim 1 was explicitly structured as a product claim for a pharmaceutical combination rather than a treatment method, protocol, or dosing schedule. The description of administration modes served merely as a functional descriptor of the product, and working examples in the specification demonstrating practical utility do not alter the product nature of the claims.
Decision
The High Court of Delhi set aside the impugned refusal order dated June 30, 2023, and remanded the patent application back to the Controller of Patents and Designs for a de novo reconsideration on its merits. The Court directed the Controller to dispose of the matter within six months from the date of receipt of the order after providing a fair opportunity of hearing to the appellant.
One Important legal principle held in the case
A pharmaceutical combination product claim is not converted into a non-patentable method of treatment under Section 3(i) of the Patents Act, 1970 merely because the claims or complete specification describe administration schedules or include working examples demonstrating practical clinical feasibility.
[Disclaimer: Readers are advised not to treat this as a substitute for legal advice as it may contain errors in perception, interpretation, and presentation ]
=====
Analytical Legal Article on Patentability of Pharmaceutical Combination Claims
Introduction:
The legal framework governing pharmaceutical patents in India strikes a delicate balance between encouraging genuine technical innovation and preventing the unwarranted extension of patent monopolies. Central to this balance are statutory provisions under the Patents Act, 1970 that exclude certain subject matters from patentability, particularly those relating to mere derivatives of known substances and methods of medical treatment. A recurrent issue in patent prosecution concerns whether claims directed to pharmaceutical combinations containing known active ingredients constitute patentable product inventions or barred therapeutic regimens. This judgment of the High Court of Delhi provides critical clarity on the threshold of inventive step, the scope of Section 3(d), and the boundaries of Section 3(i) exclusions when adjudicating pharmaceutical combination patent applications.
Factual and Procedural Background:
The subject patent application, numbered 450/DELNP/2015 and titled "PHARMACEUTICAL COMBINATION COMPRISING A BRAF INHIBITOR AN EGFR INHIBITOR AND OPTIONALLY A PI3K ALPHA INHIBITOR", originated from a priority US application filed on August 7, 2012. An international PCT application was filed on August 5, 2013, published internationally on February 13, 2014, and subsequently entered the Indian national phase on January 19, 2015. The application was published under Section 11A of the Patents Act, 1970 on June 26, 2015, and a formal request for examination was filed on August 1, 2016.
The Patent Office issued a First Examination Report on August 24, 2018, to which a detailed response was submitted on February 6, 2019. Following hearing notices, adjournments, and formal hearings held under Section 15 of the Act, along with written submissions and clinical data filed on record, the Deputy Controller of Patents and Designs issued an order on June 30, 2023. The Controller refused the patent application on the grounds of lack of inventive step under Section 2(1)(ja), non-patentability under Sections 3(d) and 3(i), and lack of clarity and definitive scope under Sections 10(4)(c) and 10(5) of the Patents Act, 1970. The applicant then preferred a statutory appeal under Section 117A before the High Court of Delhi challenging the refusal order.
Dispute Before the Court
The main dispute before the Court revolved around whether the Patent Office was justified in refusing the patent application for a pharmaceutical combination designed for the treatment of proliferative diseases such as colorectal cancer. The primary legal issue was whether the claimed combination lacked an inventive step under Section 2(1)(ja) in light of four prior art documents cited by the Patent Office. A key factual controversy pertained to whether a person skilled in the art, reading the prior art documents, would have had the motivation or reasonable expectation of success to combine the specific active pharmaceutical agents selected by the applicant.
Another essential issue was whether the subject application fell within the non-patentability bar of Section 3(d) of the Act. The Patent Office contended that the combination comprised known compounds without showing enhanced efficacy over known prior art. The applicant countered that Section 3(d) is inapplicable to a combination of distinct, independent active pharmaceutical agents having different chemical structures and mechanisms of action.
Finally, a major point of contention was the applicability of Section 3(i) of the Act, which prohibits patents for processes of medicinal or therapeutic treatment of human beings. The Patent Office argued that because the claims referenced simultaneous, separate, or sequential administration and the specification outlined clinical trial dosing protocols, the claimed invention was essentially a method of medical treatment. The applicant maintained that the claims were strictly product claims defining a pharmaceutical combination entity, and that administration descriptors and clinical examples merely demonstrated industrial applicability and practical workability.
Reasoning and Analysis of the Court
In analyzing the objection regarding lack of inventive step under Section 2(1)(ja) of the Act, the Court conducted a comprehensive, document-by-document evaluation of the four cited prior arts. Prior art D1 disclosed B-Raf inhibitors generally and taught combinations with MEK inhibitors, but provided no teaching or disclosure regarding combinations with EGFR or PI3K-alpha inhibitors. Prior art D2 focused on diagnostic and prognostic methods for detecting mutations and mentioned EGFR signaling inhibitors generally in combination with unspecified RAF inhibitors, without disclosing the specific B-Raf inhibitor Encorafenib. Prior art D3 disclosed combinations of dabrafenib with an unspecified PI3K inhibitor, but contained no reference to EGFR inhibitors such as Erlotinib or Cetuximab. Prior art D4 was directed to novel PI3K inhibitors as chemical entities and discussed in vitro models involving EGFR, but failed to disclose the specific combination claimed.
The Court concluded that none of the cited prior art documents, whether viewed individually or collectively, disclosed or suggested the specific dual combination of Encorafenib with Erlotinib or Cetuximab, or the triple combination incorporating Alpelisib. The Court observed that the Controller failed to identify the closest prior art document, articulate the specific technical problem solved by the invention, or explain how a person skilled in the art would be motivated to select and combine these specific active ingredients from a vast landscape of known compounds. Furthermore, the Court highlighted that the clinical data in the specification demonstrated significant technical advancement and synergistic therapeutic effects, including tumor regression, which had not been properly evaluated by the Controller.
Addressing the objection under Section 3(d) of the Act, the Court noted that Section 3(d) applies to the mere discovery of a new form of a known substance or derivatives unless they differ significantly in efficacy. The Court emphasized that for Section 3(d) to be invoked, the decision-maker must explicitly identify the base known compound. Relying upon the principle affirmed in Topotarget UK Ltd. vs. Controller General of Patents & Designs [IPDPTA/50/2023], the Court reiterated that a combination of two or more independent active pharmaceutical agents, each possessing a distinct chemical identity and therapeutic mechanism, cannot be treated as derivatives of each other under Section 3(d). The Controller's failure to identify any specific known compound rendered the Section 3(d) finding legally unsustainable.
On the challenge under Section 3(i) of the Act, the Court examined the structural language of Claim 1. Section 3(i) prohibits processes for therapeutic treatment, but does not exclude pharmaceutical products or combinations. The Court held that the phrase "for simultaneous, separate or sequential administration" functions merely as a descriptor defining the range of ways the constituent active ingredients in the combination product can be delivered, without transforming the product claim into a process or method step.
To reinforce this legal standard, the Court referred to established precedents including Societe Des Produits Nestle SA vs. Controller of Patents & Designs [CA (COMM).IPD-PAT) 22/2022] and Medilabo RFP Ink Inc. vs. Controller of Patents [CA (COMM).IPD-PAT) 16/2024], which established that using expressions relating to treatment or administration to define a composition does not attract Section 3(i). Furthermore, drawing upon the principles laid down in Bayer Pharma Aktiengesellschaft vs. The Controller of Patents and Design [2024:DHC:2395], the Court clarified the fundamental legal distinction between claim scope and working examples. Working examples and clinical protocols set out in a patent specification serve to demonstrate the practical feasibility and workability of an invention under Section 10(4) of the Act, but do not dictate or expand the legal boundaries of the claim itself. Since Claim 1 was drafted as a product claim for a pharmaceutical combination, Section 3(i) was completely inapplicable.
The Court also briefly evaluated principles from related jurisprudence including Ranbaxy Laboratories Ltd. vs. The Controller of Patents & Designs [OA/15/2011/PT/MUM], Ajantha Pharma Ltd. vs. Allergan Inc. & Ors. [Order No. 173/2013], Biomoneta Research Pvt. Ltd. v. Controller General of Patents & Designs [2023/DHC/001816], Zydus Lifesciences Ltd. v. ER Squibb & Sons LLC [2026:DHC:178-DB], and Novartis AG v. Union of India [(2013) 6 SCC 1]. The Court found that the Controller's rejection under Sections 10(4)(c) and 10(5) was entirely devoid of reasoning, making a complete re-examination necessary.
Final Decision of the Court
The Court set aside the impugned order dated June 30, 2023 passed by the Deputy Controller of Patents and Designs under Section 15 of the Patents Act, 1970. The matter was remanded back to the Patent Office for a de novo reconsideration of the patent application on its merits. The Court directed the Controller to afford the applicant a fair hearing and to dispose of the patent application within six months from the date of receipt of the judicial order, while clarifying that the fresh determination must be made independently without being influenced by the observations made in the judgment.
Point of Law Settled
This decision clarifies and reinforces two important principles in Indian patent law. First, it settles that a product claim directed to a pharmaceutical combination entity cannot be recharacterized as a non-patentable process or method of treatment under Section 3(i) of the Patents Act, 1970 simply because the claim describes administration modes or because the complete specification details clinical trial protocols and dosing schedules. Second, it affirms that when rejecting an application under Section 3(d) or Section 2(1)(ja), the Patent Office must specifically identify the base known compound and clearly articulate the technical problem and motivation that would lead a person skilled in the art to combine specific active pharmaceutical agents, rather than relying on generalized mosaic references to prior art.
Title of the Case: Array BioPharma Inc. vs. Deputy Controller of Patents and Designs
Date of Judgment: 23.07.2026
Case Number: C.A.(COMM.IPD-PAT) 37/2023
Neutral Citation: 2026:DHC:5856
Name of Court: High Court of Delhi at New Delhi
Name of Hon'ble Judge: Hon'ble Mr. Justice Tushar Rao Gedela
Written By:Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi
Disclaimer: Readers are advised not to treat this as a substitute for legal advice as it may contain errors in perception, interpretation, and presentation .
Headnote of the Judgment:
Array BioPharma Inc. v. Deputy Controller of Patents and Designs, High Court of Delhi, C.A.(COMM.IPD-PAT) 37/2023, Neutral Citation 2026:DHC:5856. The appellant appealed against an order of the Deputy Controller refusing patent application 450/DELNP/2015 for a pharmaceutical combination of a B-Raf inhibitor, an EGFR inhibitor, and optionally a PI3K-alpha inhibitor under Sections 2(1)(ja), 3(d), and 3(i) of the Patents Act, 1970. The High Court found that prior art documents D1 to D4 did not teach or suggest the claimed combination. The Court held Section 3(d) inapplicable as no base known compound was identified, and ruled that Section 3(i) does not bar combination product claims merely because administration modes or clinical examples are described. The High Court set aside the refusal order and remanded the matter for fresh de novo consideration within six months.
Suggested SEO Tags:
Delhi High Court, Patent Law India, Patents Act 1970, Section 3i Patents Act, Section 3d Patents Act, Section 21ja Patents Act, Pharmaceutical Combination Patents, Inventive Step Patent Law, Encorafenib Patent, B Raf Inhibitor, EGFR Inhibitor, PI3K Alpha Inhibitor, Cancer Drug Patent, Patent Office Remand Order, Method of Treatment Exclusion, Working Examples Patent Claims, Patent Efficacy Section 3d, Combination Therapy Patents, Indian Patent Jurisprudence, IP Litigation Delhi High Court, Controller of Patents Refusal, Patent Application Remand, Pharmaceutical Patent Prosecution, High Court Patent Appeal, Section 117A Patents Act, AdvocateAjayAmitabhSuman, IPAdjutor.
Suggested SEO Titles:
Delhi High Court Remands Array BioPharma Cancer Combination Patent Application for Fresh Hearing
Understanding Section 3(i) of Patents Act: Why Combination Products Are Not Methods of Treatment
Delhi High Court Clarifies Patentability of Pharmaceutical Combinations under Indian Patent Law
Array BioPharma Patent Appeal: Delhi HC Overturns Refusal of BRAF and EGFR Inhibitor Claims
Inventive Step and Prior Art Analysis in Pharmaceutical Patent Applications: Delhi HC Ruling
Demystifying Section 3(d) and 3(i) Objections in Indian Patent Law: Lessons from Array BioPharma
Working Examples vs Claim Scope: Delhi High Court Analysis on Patentability of Cancer Drug Combinations
Delhi High Court Sets Aside Patent Office Refusal for Multi Target Cancer Therapy Patent
Legal Insights on Pharmaceutical Combination Claims and Section 3(i) Exclusion in India
Array BioPharma v Deputy Controller of Patents: Analysis of Delhi High Court Remand Order
